Truist Financial analyst Richard Newitter maintains $Glaukos (GKOS.US)$ with a buy rating.
According to TipRanks data, the analyst has a success rate of 58.7% and a total average return of 17.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Glaukos (GKOS.US)$'s main analysts recently are as follows:
Glaukos' third-quarter outcomes surpassed consensus projections, bolstered by an $8.8 million contribution from iDose and a 12.3% increase in the iStent infinite and the broader iStent portfolio within the U.S. market. Additionally, the company's glaucoma business is experiencing robust growth of over 20% internationally.
Glaukos' Q3 sales exceeded expectations, bolstered by the performance of iDose and international sales in the minimally invasive glaucoma surgery (MIGS) sector. Following this trend, the company's management increased their sales guidance by $5 million, aligning with the scale of this outperformance. It appears that there is positive momentum for iDose looking into Q4 and beyond, towards 2025.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
儲億銀行分析師Richard Newitter維持$Glaukos (GKOS.US)$買入評級。
根據TipRanks數據顯示，該分析師近一年總勝率為58.7%，總平均回報率為17.8%。
此外，綜合報道，$Glaukos (GKOS.US)$近期主要分析師觀點如下：
glaukos第三季度業績超出共識預期，主要得益於iDose貢獻了880萬美元，並且在美國市場中，iStent infinite和更廣泛的iStent組合增長了12.3%。此外，公司的青光眼業務在國際市場上實現了超過20%的強勁增長。
glaukos第三季度銷售超出預期，主要受益於iDose的表現和微創青光眼手術（MIGS）板塊在國際銷售方面的增長。在這一趨勢下，公司管理層將銷售指導額增加了500萬美元，與這一超常表現的規模保持一致。看起來iDose在第四季度以及未來朝2025年迎來了積極的勢頭。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
